Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19509621 | 0.91 | NOTUM (0.53) | NOTUMDPP4L3MBTL1P2RX7KDM4E | |
| SCHEMBL21802463 | 0.89 | NOTUM (0.51) | NOTUMDPP4L3MBTL1P2RX7KDM4E | |
| SCHEMBL5654651 | 0.87 | NOTUM (0.50) | NOTUMDPP4L3MBTL1P2RX7GBA1 | |
| SCHEMBL1345911 | 0.87 | DPP4 (0.51) | NOTUMDPP4L3MBTL1P2RX7KDM4E | |
| SCHEMBL17084383 | 0.84 | GBA1 (0.51) | NOTUMGBA1 | |
| SCHEMBL15409578 | 0.82 | NOTUM (0.46) | NOTUMDPP4L3MBTL1GBA1 | |
| SCHEMBL12788075 | 0.82 | GBA1 (0.57) | GBA1 | |
| SCHEMBL1345747 | 0.82 | — | — | |
| SCHEMBL22807655 | 0.82 | — | — | |
| SCHEMBL22044545 | 0.81 | NOTUM (0.45) | NOTUMDPP4L3MBTL1P2RX7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238322-A1 | THERAPEUTIC AGENTS AND METHODS OF PRODUCING SAME | Glycosynnovations Pty Ltd (AU) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238322-A1 | THERAPEUTIC AGENTS AND METHODS OF PRODUCING SAME | SIGLEC7, FUT5, UGCG | NOTUM 483/4885DPP4 471/4885L3MBTL1 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.